DE602004022674D1 - Zusammensetzung die mindestens ein cdc25-phosphatase inhibitor und mindestens ein anderes anti-krebs mittel - Google Patents

Zusammensetzung die mindestens ein cdc25-phosphatase inhibitor und mindestens ein anderes anti-krebs mittel

Info

Publication number
DE602004022674D1
DE602004022674D1 DE602004022674T DE602004022674T DE602004022674D1 DE 602004022674 D1 DE602004022674 D1 DE 602004022674D1 DE 602004022674 T DE602004022674 T DE 602004022674T DE 602004022674 T DE602004022674 T DE 602004022674T DE 602004022674 D1 DE602004022674 D1 DE 602004022674D1
Authority
DE
Germany
Prior art keywords
composition
phosphatase inhibitor
cdc25 phosphatase
cancer medium
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004022674T
Other languages
German (de)
English (en)
Inventor
Gregoire Prevost
Pannetier Marie-Christine Brezak
Christian Diolez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Ipsen Pharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma SAS filed Critical Ipsen Pharma SAS
Publication of DE602004022674D1 publication Critical patent/DE602004022674D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602004022674T 2003-06-25 2004-06-24 Zusammensetzung die mindestens ein cdc25-phosphatase inhibitor und mindestens ein anderes anti-krebs mittel Expired - Lifetime DE602004022674D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0307649A FR2856688B1 (fr) 2003-06-25 2003-06-25 PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
PCT/FR2004/001586 WO2005000852A2 (fr) 2003-06-25 2004-06-24 Produit comprenant au moins un inhibiteur de phosphates cdc25 en association avec au moins un autre agent anti-cancereux

Publications (1)

Publication Number Publication Date
DE602004022674D1 true DE602004022674D1 (de) 2009-10-01

Family

ID=33515382

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004022674T Expired - Lifetime DE602004022674D1 (de) 2003-06-25 2004-06-24 Zusammensetzung die mindestens ein cdc25-phosphatase inhibitor und mindestens ein anderes anti-krebs mittel

Country Status (14)

Country Link
US (3) US20060281736A1 (enExample)
EP (3) EP1792905A1 (enExample)
JP (2) JP2007514639A (enExample)
AR (2) AR044930A1 (enExample)
AT (1) ATE439836T1 (enExample)
CA (1) CA2530668A1 (enExample)
DE (1) DE602004022674D1 (enExample)
DK (1) DK1641453T3 (enExample)
ES (1) ES2332137T3 (enExample)
FR (1) FR2856688B1 (enExample)
MX (1) MXPA06000216A (enExample)
MY (1) MY141725A (enExample)
PL (1) PL1641453T3 (enExample)
WO (1) WO2005000852A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2834289B1 (fr) 2001-12-27 2004-03-19 Sod Conseils Rech Applic Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques
ATE368654T1 (de) * 2001-12-27 2007-08-15 Sod Conseils Rech Applic Benzothiazol- und benzoxazol-4,7-dionderivate und ihre verwendung als cdc25-phosphatasen- inhibitoren
FR2856688B1 (fr) * 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
DE10353792A1 (de) 2003-11-13 2005-06-23 Exner, Heinrich, Dr.med.vet. Heil- und Wundsalbe auf der Basis einer wässrigen Emulsion
FR2877667B1 (fr) 2004-11-05 2007-03-23 Sod Conseils Rech Applic Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques
FR2879598B1 (fr) 2004-12-17 2007-03-30 Sod Conseils Rech Applic Inhibiteurs de phosphatases cdc25
FR2879460B1 (fr) * 2004-12-17 2007-02-23 Sod Conseils Rech Applic Associations anti-douleur comprenant un derive de dihydroimidazopyrazine
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US8222342B2 (en) * 2007-09-06 2012-07-17 Basf Se Blends from branched polyaryl ethers and hydrophilic polymers
WO2009100375A1 (en) 2008-02-06 2009-08-13 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
JO3156B1 (ar) 2009-07-09 2017-09-20 Novartis Ag ايميدازولات مدمجة والتركيبات التي تشملها لعلاج الأمراض الطفيلية على مثال الملاريا
HUE042801T2 (hu) 2010-11-12 2019-07-29 Pharma Mar Sa Kombinációs terápia mitózisgátlóval
TWI791515B (zh) 2017-04-24 2023-02-11 瑞士商諾華公司 治療療法
US20210106567A1 (en) * 2019-10-01 2021-04-15 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for inhibiting carp-1 binding to nemo
PH12022551216A1 (en) 2019-11-21 2023-07-17 Pharma Mar Sa Methods of treating small cell lung cancer with lurbinectedin formulations
US11981645B1 (en) 2023-10-10 2024-05-14 King Faisal University N′-(2-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as antimicrobial compound

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US735674A (en) * 1902-01-29 1903-08-04 William C Matthias Sparking igniter for explosive-engines.
FR50000E (fr) 1938-11-29 1939-09-29 Moulin à café
US5523430A (en) * 1994-04-14 1996-06-04 Bristol-Myers Squibb Company Protein farnesyl transferase inhibitors
US6673927B2 (en) * 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
US6383871B1 (en) * 1999-08-31 2002-05-07 Micron Technology, Inc. Method of forming multiple oxide thicknesses for merged memory and logic applications
EP1233787B8 (fr) * 1999-11-09 2005-05-18 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Produit comprenant un inhibiteur de la transduction des signaux des proteines g heterotrimeriques en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
FR2812198B1 (fr) * 2000-07-28 2008-07-18 Sod Conseils Rech Applic DERIVES D'AMIDINES INHIBITEURS DE PHOSPHATASES cdc25
CA2432417A1 (fr) * 2000-12-20 2002-06-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R .A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
FR2825278A1 (fr) * 2001-05-30 2002-12-06 Sod Conseils Rech Applic Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
AR037714A1 (es) * 2001-12-06 2004-12-01 Maxia Pharmaceuticals Inc Derivados de tiazolidinona y oxazolidinona 2-sustituidos para la inhibicion de fosfatasas y el tratamiento de cancer
FR2834289B1 (fr) * 2001-12-27 2004-03-19 Sod Conseils Rech Applic Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques
ATE368654T1 (de) * 2001-12-27 2007-08-15 Sod Conseils Rech Applic Benzothiazol- und benzoxazol-4,7-dionderivate und ihre verwendung als cdc25-phosphatasen- inhibitoren
FR2856686A1 (fr) * 2003-06-25 2004-12-31 Sod Conseils Rech Applic Benzothiazole-4,7-diones et benzooxazole-4,7-diones substituees en position 5 ou 6 et leurs procedes de preparation
FR2856688B1 (fr) * 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
JP4273056B2 (ja) * 2004-08-12 2009-06-03 不二越機械工業株式会社 研磨装置

Also Published As

Publication number Publication date
ES2332137T3 (es) 2010-01-27
EP1792905A1 (fr) 2007-06-06
JP2007514639A (ja) 2007-06-07
JP2009149694A (ja) 2009-07-09
WO2005000852A2 (fr) 2005-01-06
EP1641453A2 (fr) 2006-04-05
DK1641453T3 (da) 2009-12-14
ATE439836T1 (de) 2009-09-15
EP2335702A1 (fr) 2011-06-22
US20090137596A1 (en) 2009-05-28
AR070977A2 (es) 2010-05-19
CA2530668A1 (fr) 2005-01-06
US20060281736A1 (en) 2006-12-14
MXPA06000216A (es) 2006-04-11
MY141725A (en) 2010-06-15
PL1641453T3 (pl) 2010-01-29
EP1641453B1 (fr) 2009-08-19
AR044930A1 (es) 2005-10-12
US20090253685A1 (en) 2009-10-08
WO2005000852A3 (fr) 2005-06-30
FR2856688A1 (fr) 2004-12-31
FR2856688B1 (fr) 2008-05-30

Similar Documents

Publication Publication Date Title
DE602004022674D1 (de) Zusammensetzung die mindestens ein cdc25-phosphatase inhibitor und mindestens ein anderes anti-krebs mittel
MX2008006598A (es) Composiciones de edulcorante de alta potencia con vitamina y composiciones edulcoradas con la misma
DK2277976T3 (da) Sammensætninger omfattende hfc-1234ze og smøremiddel
DE60332475D1 (de) Zusammensetzungen verwendbar für die hemmung von rock und anderen kinasen
EP1803799A4 (en) LUBRICANT FORMULA AND ANTIOXIDANT FORMULA
DK1711470T3 (da) Malonamidderivater der blokerer aktiviteten af gamma-sekretase
ATE435859T1 (de) Gyraseinhibitoren und deren verwendungen
DE602005004988D1 (de) Reversibele thermochromische Zusammensetzung und Mikrokapseln, die diese enthalten
MX2008006592A (es) Composiciones de edulcorante de alta potencia con calcio y composiciones edulcoradas con la misma
DE60333020D1 (de) Anzeigeeinrichtung des dünnen typs
DE602004010329D1 (de) Fett- oder Ölzusammensetzung
SE0303596L (sv) Ny banprodukt av metall
DE60317799D1 (de) Antimikrobielle zusammensetzung und anwendungsverfahren
ATE539138T1 (de) Schmierstoffzusammensetzungen
FI20021660A0 (fi) Hiilihydraattien uusi käyttö ja koostumukset
FI20031190L (fi) Antioksidantti ja sen käyttö
EP1959922A4 (en) COSMETIC COMPOSITION WITH CAPTURED PIGMENTS AND METHOD OF USE THEREOF
NO20043937L (no) Anvendelse av vitamin D sammensetninger
EP1874348A4 (en) IMMUNOREGULATORY COMPOSITIONS AND THEIR USE
EP1899575A4 (en) INVERSE EMULSION CARRIER FLUID AND OILY AGENT AND METHOD OF USE THEREOF
EP1521589A4 (en) BIOACTIVATION OF PARTICLES
DE502004008541D1 (de) Schmierger t und ein solches aufweisende abschmiereinrichtun g
EP1924684A4 (en) Transition state structure of 5'-methylthioadenosine/s-adenosylhomocysteine nucleosidases
IS8399A (is) Form fjölgervings 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólíns
FI20021431A7 (fi) Voiteluöljy ja sen käyttö

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: PREVOST, GREGOIRE, F-92160 ANTONY, FR

Inventor name: BREZAK PANNETIER, MARIE-CHRISTINE, F-92160 ANT, FR

8364 No opposition during term of opposition